Conventional pharmacologic therapies for RA treatment include disease-modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX) and biological agents that selectively block cytokines, such as anti-TNF-α antibodies. This evidence concerns the gene TNF and rheumatoid arthritis.